MSA
INMB icon

Marino Stram & Associates’s INmune Bio INMB Stock Holding History

Marino Stram & Associates’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,369
Closed -$182K – 211
2021
Q2 		$182K Buy
+10,369
New +$140K 0.05% 245

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Marino Stram & Associates's INMB Position: Q3 2021 in Review

Marino Stram & Associates sold out of INmune Bio (INMB) in Q3 2021, closing a stake of 10,369 shares — an estimated $182K sold.

Marino Stram & Associates first reported a position in INMB in Q2 2021 and held it in 1 quarter. The position peaked at $182K in Q2 2021. 41 funds tracked by Wall St. Rank hold INMB as of Q3 2021.

  • Marino Stram & Associates reported no remaining INmune Bio position as of Q3 2021 after selling out during the quarter.
  • Marino Stram & Associates sold 10,369 INmune Bio shares in Q3 2021, an estimated $182K.
  • Marino Stram & Associates first reported a position in INmune Bio in Q2 2021 and held it in 1 quarter.
  • Marino Stram & Associates's INmune Bio position peaked at $182K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held INmune Bio as of Q3 2021.

Based on Marino Stram & Associates's 13F filing for Q3 2021, filed 14 Oct 2021.